James J. Dolan
Profile
James J.
Dolan held several positions in the pharmaceutical industry, including Principal at Pfizer Inc., SVP-Licensing & Business Development at Purdue Pharma LP, and Board Observer at Kolltan Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc., and Novelos Therapeutics, Inc. He also served as President of New York Pharma Forum, Inc. Dolan earned an MBA from the University of Connecticut and an undergraduate degree from Holy Cross College (Indiana).
Former positions of James J. Dolan
| Companies | Position | End |
|---|---|---|
New York Pharma Forum, Inc.
 New York Pharma Forum, Inc. Information Technology ServicesTechnology Services New York Pharma Forum, Inc. provides information technology services for the healthcare industry. The private company is based in New York, NY. | President | - |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Corporate Officer/Principal | - |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Corporate Officer/Principal | - |
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Training of James J. Dolan
| Holy Cross College (Indiana) | Undergraduate Degree |
| University of Connecticut | Masters Business Admin |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Purdue Pharma LP
 Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
New York Pharma Forum, Inc.
New York Pharma Forum, Inc. Information Technology ServicesTechnology Services New York Pharma Forum, Inc. provides information technology services for the healthcare industry. The private company is based in New York, NY. | Technology Services |
- Stock Market
- Insiders
- James J. Dolan
